Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.02
-0.08 (-1.57%)
Mar 12, 2026, 3:35 PM EDT - Market open
Candel Therapeutics Market Cap
Candel Therapeutics has a market cap or net worth of $367.7 million as of March 12, 2026. Its market cap has increased by 3.24% in one year.
Market Cap
367.70M
Enterprise Value
296.27M
1-Year Change
3.24%
Ranking
Category
Stock Price
$5.02
Market Cap Chart
Since the IPO on July 27, 2021, Candel Therapeutics's market cap has increased from $222.39M to $367.70M, an increase of 65.34%. That is a compound annual growth rate of 11.49%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 11, 2026 | 373.56M | 20.43% |
| Dec 31, 2025 | 310.18M | -15.87% |
| Dec 31, 2024 | 368.69M | 767.25% |
| Dec 29, 2023 | 42.51M | -17.80% |
| Dec 30, 2022 | 51.72M | -76.95% |
| Dec 31, 2021 | 224.35M | 0.88% |
| Jul 27, 2021 | 222.39M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Niagen Bioscience | 392.41M |
| Monopar Therapeutics | 380.91M |
| X4 Pharmaceuticals | 378.60M |
| LENZ Therapeutics | 376.11M |
| NovaBridge Biosciences | 371.24M |
| Absci | 368.41M |
| Greenwich LifeSciences | 368.12M |
| Immuneering | 365.29M |